Cargando…

2239. Colorectal Cancer Screening Rates and Outcomes in HIV-Infected and HIV-Uninfected Individuals

BACKGROUND: As people with HIV live longer, age-appropriate colorectal cancer (CRC) screening will be an increasingly important component of care. However, it remains unclear whether CRC screening guidelines for the general population, which recommend screening of average-risk persons starting at ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Lam, Jennifer, Hurley, Leo, Udaltsova, Natalia, Alexeeff, Stacey, Klein, Daniel, Corley, Douglas, Silverberg, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252990/
http://dx.doi.org/10.1093/ofid/ofy210.1892
_version_ 1783373392940892160
author Lam, Jennifer
Hurley, Leo
Udaltsova, Natalia
Alexeeff, Stacey
Klein, Daniel
Corley, Douglas
Silverberg, Michael
author_facet Lam, Jennifer
Hurley, Leo
Udaltsova, Natalia
Alexeeff, Stacey
Klein, Daniel
Corley, Douglas
Silverberg, Michael
author_sort Lam, Jennifer
collection PubMed
description BACKGROUND: As people with HIV live longer, age-appropriate colorectal cancer (CRC) screening will be an increasingly important component of care. However, it remains unclear whether CRC screening guidelines for the general population, which recommend screening of average-risk persons starting at age 50, are appropriate for people with HIV particularly those with advanced HIV disease. METHODS: We compared CRC screening rates and outcomes among HIV-infected and demographically-matched HIV-uninfected subjects in a large integrated healthcare system. Using electronic health records, we identified subjects aged 50–75 years during 2005 to 2016 with no prior CRC screening. We evaluated time to first CRC screen (FIT, sigmoidoscopy or colonoscopy) using Kaplan–Meier estimates, and compared adenoma and CRC prevalence following first sigmoidoscopy or colonoscopy, by HIV status. Adjusted prevalence ratios (PR) accounted for sex, age, race, smoking status, body mass index, and diagnosis of type 2 diabetes or inflammatory bowel disease. Among HIV-infected subjects, we also evaluated whether CD4 count (<200, 200–499, ≥500) was associated with screening outcome. RESULTS: Among 3,177 HIV-infected and 29,219 HIV-uninfected CRC screening-eligible subjects, HIV-infected subjects were more likely to be screened within 5 years of health plan enrollment or turning 50 (85.6% vs. 79.1%, P < 0.001). Among those with a sigmoidoscopy or colonoscopy, adenoma was detected in 161 (19.6%) HIV-infected and 1,498 (22.6%) HIV-uninfected subjects (P = 0.048) and CRC was detected in 4 (0.5%) HIV-infected and 69 (1.0%) HIV-uninfected subjects (P = 0.13). We found suggestion of a lower prevalence of adenoma and CRC among HIV-infected subjects, which only reached statistical significance in unadjusted models (unadjusted PR: 0.86, 95% CI: 0.75–1.00, P < 0.049; adjusted PR: 0.89, 95% CI: 0.77–1.03, P = 0.134). Lower CD4 count did not increase likelihood of a positive CRC screening result. CONCLUSION: In a setting with overall high screening uptake, we found similar adenoma and CRC prevalence in individuals with and without HIV. Our findings suggest that current CRC screening guidelines for the general population are also suitable for the HIV population. DISCLOSURES: M. Silverberg, Gilead: Grant Investigator, Grant recipient.
format Online
Article
Text
id pubmed-6252990
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62529902018-11-28 2239. Colorectal Cancer Screening Rates and Outcomes in HIV-Infected and HIV-Uninfected Individuals Lam, Jennifer Hurley, Leo Udaltsova, Natalia Alexeeff, Stacey Klein, Daniel Corley, Douglas Silverberg, Michael Open Forum Infect Dis Abstracts BACKGROUND: As people with HIV live longer, age-appropriate colorectal cancer (CRC) screening will be an increasingly important component of care. However, it remains unclear whether CRC screening guidelines for the general population, which recommend screening of average-risk persons starting at age 50, are appropriate for people with HIV particularly those with advanced HIV disease. METHODS: We compared CRC screening rates and outcomes among HIV-infected and demographically-matched HIV-uninfected subjects in a large integrated healthcare system. Using electronic health records, we identified subjects aged 50–75 years during 2005 to 2016 with no prior CRC screening. We evaluated time to first CRC screen (FIT, sigmoidoscopy or colonoscopy) using Kaplan–Meier estimates, and compared adenoma and CRC prevalence following first sigmoidoscopy or colonoscopy, by HIV status. Adjusted prevalence ratios (PR) accounted for sex, age, race, smoking status, body mass index, and diagnosis of type 2 diabetes or inflammatory bowel disease. Among HIV-infected subjects, we also evaluated whether CD4 count (<200, 200–499, ≥500) was associated with screening outcome. RESULTS: Among 3,177 HIV-infected and 29,219 HIV-uninfected CRC screening-eligible subjects, HIV-infected subjects were more likely to be screened within 5 years of health plan enrollment or turning 50 (85.6% vs. 79.1%, P < 0.001). Among those with a sigmoidoscopy or colonoscopy, adenoma was detected in 161 (19.6%) HIV-infected and 1,498 (22.6%) HIV-uninfected subjects (P = 0.048) and CRC was detected in 4 (0.5%) HIV-infected and 69 (1.0%) HIV-uninfected subjects (P = 0.13). We found suggestion of a lower prevalence of adenoma and CRC among HIV-infected subjects, which only reached statistical significance in unadjusted models (unadjusted PR: 0.86, 95% CI: 0.75–1.00, P < 0.049; adjusted PR: 0.89, 95% CI: 0.77–1.03, P = 0.134). Lower CD4 count did not increase likelihood of a positive CRC screening result. CONCLUSION: In a setting with overall high screening uptake, we found similar adenoma and CRC prevalence in individuals with and without HIV. Our findings suggest that current CRC screening guidelines for the general population are also suitable for the HIV population. DISCLOSURES: M. Silverberg, Gilead: Grant Investigator, Grant recipient. Oxford University Press 2018-11-26 /pmc/articles/PMC6252990/ http://dx.doi.org/10.1093/ofid/ofy210.1892 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Lam, Jennifer
Hurley, Leo
Udaltsova, Natalia
Alexeeff, Stacey
Klein, Daniel
Corley, Douglas
Silverberg, Michael
2239. Colorectal Cancer Screening Rates and Outcomes in HIV-Infected and HIV-Uninfected Individuals
title 2239. Colorectal Cancer Screening Rates and Outcomes in HIV-Infected and HIV-Uninfected Individuals
title_full 2239. Colorectal Cancer Screening Rates and Outcomes in HIV-Infected and HIV-Uninfected Individuals
title_fullStr 2239. Colorectal Cancer Screening Rates and Outcomes in HIV-Infected and HIV-Uninfected Individuals
title_full_unstemmed 2239. Colorectal Cancer Screening Rates and Outcomes in HIV-Infected and HIV-Uninfected Individuals
title_short 2239. Colorectal Cancer Screening Rates and Outcomes in HIV-Infected and HIV-Uninfected Individuals
title_sort 2239. colorectal cancer screening rates and outcomes in hiv-infected and hiv-uninfected individuals
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252990/
http://dx.doi.org/10.1093/ofid/ofy210.1892
work_keys_str_mv AT lamjennifer 2239colorectalcancerscreeningratesandoutcomesinhivinfectedandhivuninfectedindividuals
AT hurleyleo 2239colorectalcancerscreeningratesandoutcomesinhivinfectedandhivuninfectedindividuals
AT udaltsovanatalia 2239colorectalcancerscreeningratesandoutcomesinhivinfectedandhivuninfectedindividuals
AT alexeeffstacey 2239colorectalcancerscreeningratesandoutcomesinhivinfectedandhivuninfectedindividuals
AT kleindaniel 2239colorectalcancerscreeningratesandoutcomesinhivinfectedandhivuninfectedindividuals
AT corleydouglas 2239colorectalcancerscreeningratesandoutcomesinhivinfectedandhivuninfectedindividuals
AT silverbergmichael 2239colorectalcancerscreeningratesandoutcomesinhivinfectedandhivuninfectedindividuals